Phase II Trial of Temporary Androgen Deprivation Therapy in High Risk Prostate Cancer Following Radical Prostatectomy.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Goserelin (Primary) ; Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 May 2011 Planned End Date changed from 1 Dec 2022 to 1 Dec 2013 as reported by ClinicalTrials.gov.